Technical Analysis for OKUR - OnKure Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | -2.75% | |
| Fell Below 200 DMA | Bearish | -2.81% | |
| 180 Bearish Setup | Bearish Swing Setup | -2.81% | |
| NR7 | Range Contraction | -2.81% | |
| Narrow Range Bar | Range Contraction | -2.81% | |
| Inside Day | Range Contraction | -2.81% | |
| Bullish Engulfing | Bullish | -5.13% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 14 hours ago |
| Possible Inside Day | about 14 hours ago |
| Down 2 % | about 17 hours ago |
| Down 1% | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Personalized Medicine Drug Design
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Personalized Medicine Drug Design
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 77.6 |
| 52 Week Low | 9.801 |
| Average Volume | 55,329 |
| 200-Day Moving Average | 16.26 |
| 50-Day Moving Average | 16.74 |
| 20-Day Moving Average | 16.84 |
| 10-Day Moving Average | 16.46 |
| Average True Range | 1.05 |
| RSI (14) | 36.31 |
| ADX | 34.89 |
| +DI | 6.51 |
| -DI | 22.70 |
| Chandelier Exit (Long, 3 ATRs) | 15.34 |
| Chandelier Exit (Short, 3 ATRs) | 17.86 |
| Upper Bollinger Bands | 18.25 |
| Lower Bollinger Band | 15.43 |
| Percent B (%b) | 0.04 |
| BandWidth | 16.74 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.14 |
| MACD Histogram | -0.196 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.42 | ||||
| Resistance 3 (R3) | 16.51 | 16.30 | 16.28 | ||
| Resistance 2 (R2) | 16.30 | 16.08 | 16.26 | 16.23 | |
| Resistance 1 (R1) | 15.93 | 15.94 | 15.83 | 15.84 | 16.18 |
| Pivot Point | 15.72 | 15.72 | 15.67 | 15.68 | 15.72 |
| Support 1 (S1) | 15.35 | 15.50 | 15.25 | 15.26 | 14.92 |
| Support 2 (S2) | 15.14 | 15.36 | 15.10 | 14.87 | |
| Support 3 (S3) | 14.77 | 15.14 | 14.83 | ||
| Support 4 (S4) | 14.68 |
